Although all enrolled participates have received anti-HER2 therapies including 77.8% (14/18) with trastuzumab resistance, IAH0968 monotherapy still achieved promising efficacy with an ORR of 13.3% and 53.3% DCR, and an even higher 40% ORR and 80% DCR in patients with heavily pretreated HER2+ CRC and BTC. Here, ERBB2 is linked to colorectal carcinoma.